IBB News Alert Nasdaq Biotechnology Ishares (IBB) 299.80 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 299.80 $IBB

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), FBT: 100.93 (+1.47), BIB: 122.51 (+3.83), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BBH: 113.91 (+1.89), ABBV: 66.21 (+1.86)

Why I Expect The Biotech Sell-Off To Continue Into 2015
Sammy Pollack - at Seeking Alpha - Wed Dec 24, 7:08AM CST

BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), AMGN: 160.67 (+3.15), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Cramer's Mad Money - Navigator Holdings Has Been Unfairly Punished (12/23/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 24, 4:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 23. Navigator Holdings (NYSE: NVGS ) Has Been Unfairly Punished . Other stock mentioned: Transocean (NYSE: RIG ) With the surge in stocks, it...
RH: 96.97 (-0.16), GD: 141.54 (+0.23), LMT: 196.43 (+0.66), HON: 101.96 (-0.02), RTN: 110.47 (+0.29), NOC: 151.76 (+0.44), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), IBB: 299.80 (+5.12), VSAT: 63.75 (-0.20), NVGS: 20.00 (+2.10), JACK: 78.82 (-0.17), RIG: 18.77 (-0.37), Q: 59.48 (+0.01), COST: 143.65 (-0.50), WAG: 76.67 (+0.16), ETN: 69.30 (-0.09), MDSO: 47.27 (+0.15), DIS: 94.42 (-0.27), WFC: 55.34 (-0.13), PLKI: 55.50 (+0.01), BA: 131.24 (+1.21), DENN: 9.96 (+0.05), CBRL: 138.16 (+0.46), GILD: 91.29 (+1.84), CVX: 113.47 (-0.48)

Jim Cramer's 'Mad Money' Recap: Here Are 10 Stocks to Buy on Strong GDP Data
at The Street - Tue Dec 23, 7:26PM CST
Kimberly-Clark, Walgreen and Starbucks are among Cramer's winners on today's GDP number.
RH: 96.97 (-0.16), EYES: 11.01 (+0.86), ETN: 69.30 (-0.09), HON: 101.96 (-0.02), KMB: 117.77 (-0.21), IBB: 299.80 (+5.12), BMY: 59.15 (-0.01), PLKI: 55.50 (+0.01), MAR: 78.35 (-0.19), BA: 131.24 (+1.21), RRC: 55.73 (-1.27), VSAT: 63.75 (-0.20), SBUX: 81.27 (-0.16), NVGS: 20.00 (+2.10), COG: 30.21 (-0.39), GILD: 91.29 (+1.84), GWPH: 68.08 (+1.82), STI: 42.43 (-0.18), COST: 143.65 (-0.50), AI: 27.70 (-0.12), WAG: 76.67 (+0.16), PSEC: 8.59 (-0.02), EPD: 35.45 (+0.25)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 4.65% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:40PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $292.04 to a high of $309.94. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $306.37 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 299.80 (+5.12)

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.65% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:39PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $292.04 to a high of $309.94. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $306.37 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 299.80 (+5.12)

Investors Should Stay Long Stocks as Market Continues Hitting Highs
at The Street - Tue Dec 23, 2:01PM CST
The CNBC 'Fast Money Halftime' trading panel knows there could be some risks in 2015.
AMZN: 303.03 (-3.26), IBB: 299.80 (+5.12), ALSN: 33.94 (+0.05), BAC: 17.98 (+0.05), TLT: 123.95 (+0.41), GOOG: 528.77 (-1.82), ESRX: 85.48 (-0.40), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), GILD: 91.29 (+1.84), DIA: 180.03 (unch), APA: 64.05 (-1.38), ABBV: 66.21 (+1.86), BP: 38.95 (-0.17), GOOGL: 536.93 (-1.84), IWM: 119.76 (-0.10), XLE: 80.13 (-0.59)

Inside The 2 New Innovative Biotech ETFs From BioShares
Zacks Funds - Seeking Alpha - Tue Dec 23, 2:00PM CST
The biotechnology corner of the broader health care industry has been one of the best performing U.S. sectors this year despite some temporary glitches and rough trading in between. Encouraging industry trends, increasing merger and acquisition...
BBP: 25.60 (+0.38), BBC: 26.85 (+0.48), FBT: 100.93 (+1.47), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12)

Fed's Patience Puts Bulls In A Hurry
Scott Martindale - Seeking Alpha - Tue Dec 23, 11:08AM CST
U.S. stocks found support once again last week and rallied on strong volume. Of course, the main catalyst was the FOMC policy statement on Wednesday that maintained its dovish language with a pledge of considerable time before raising the fed funds...
DEF: 38.15 (-0.96), NFO: 49.34 (-0.38), PNW: 69.59 (+1.41), UTHR: 130.22 (+2.40), ED: 66.91 (+0.90), IBB: 299.80 (+5.12), LUV: 41.66 (+0.68), IYZ: 29.52 (-0.18), LYB: 81.31 (-0.89), SPY: 207.77 (+0.02), IDU: 120.07 (+1.13), IYW: 106.52 (-0.41), IYK: 106.07 (-0.66), IYJ: 108.21 (-0.61), IYH: 144.69 (+0.58), BCR: 169.10 (-0.44), IYM: 83.15 (-0.74), IYC: 137.57 (-0.15), NXPI: 76.75 (+0.48), FUTY: 31.00 (+0.60), IYF: 91.09 (-0.41), IYE: 45.37 (-0.54), PYZ: 53.07 (+0.10), SHW: 264.55 (+1.46), KNOW: 69.79 (+0.15)

Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 11:02AM CST
Gilead shares fell more than 10 percent in Monday trading following news that AbbVie and Express Scripts signed an exclusive Hepatitis C.
PBE: 49.81 (+0.69), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), BBH: 113.91 (+1.89), ABBV: 66.21 (+1.86)

Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST

BIS: 47.26 (-1.74), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), BIB: 122.51 (+3.83), IBB: 299.80 (+5.12), ABBV: 66.21 (+1.86)

Inside the Two New Innovative Biotech ETFs from BioShares - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:02AM CST
Two interesting ETFs hit the market from BioShares targeting Clinical Trials and Biotechnology Products.
BBP: 25.60 (+0.38), BBC: 26.85 (+0.48), FBT: 100.93 (+1.47), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12)

AbbVie Versus Gilead In Hepatitis C, With Comments On Biotech
DoctoRx - Seeking Alpha - Mon Dec 22, 1:09PM CST
Background : I have written more than once about a comparison of the entrants from Gilead Sciences (NASDAQ: GILD ) and AbbVie (NYSE: ABBV ) for hepatitis C. Now that AbbVie's Viekira Pak has been approved for marketing by the FDA (before the close...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), ABBV: 66.21 (+1.86)

No Bargains in Rising Market: Why Not Buy High and Sell Higher?
at The Street - Mon Dec 22, 11:29AM CST
It is a rare and risky strategy, though some funds are proving it can be hugely rewarding.
MMTM: 88.10 (unch), MTUM: 68.74 (-0.14), IBB: 299.80 (+5.12), FXH: 60.73 (+0.42)

3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

Bioshares New Equal Weight ETFs Offer Diversification And Growth
Chris Katje - at Seeking Alpha - Mon Dec 22, 10:01AM CST

BBP: 25.60 (+0.38), BBC: 26.85 (+0.48), IBB: 299.80 (+5.12), FXH: 60.73 (+0.42), XLV: 68.64 (+0.50)

GW Pharmaceuticals Added to NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 22, 1:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective at the open of U.S. markets today.
GWPH: 68.08 (+1.82), IBB: 299.80 (+5.12)

The Markets Will Sink In Titanic Fashion
Papa of Four - at Seeking Alpha - Sat Dec 20, 8:08PM CST

USO: 21.05 (-0.51), F: 15.30 (-0.03), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), GCI: 31.68 (-0.20), GLD: 112.77 (+0.03), DIA: 180.03 (unch), SNE: 21.32 (+0.46), IBB: 299.80 (+5.12), GM: 33.43 (-0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading